Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPPIK: Sparsentan in Pediatric Proteinuric Glomerular Diseases
NCT05003986Phase 2Recruiting
- Sponsor
- Travere Therapeutics
- Start
- Aug 2021
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of sparsentan in focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), immunoglobulin A nephropathy (IgAN), immunoglobulin A vasculitis, Alport syndrome, sponsored by Travere Therapeutics. Started Aug 2021; status: recruiting.
02
Drugs
sparsentan
03
Conditions
focal segmental glomerulosclerosis (FSGS)minimal change disease (MCD)immunoglobulin A nephropathy (IgAN)immunoglobulin A vasculitisAlport syndrome
Beyond the preview
Go deeper on NCT05003986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05003986.